Dr Reddy’s expands collaboration with Amgen in India

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Dr Reddy’s expands collaboration with Amgen in India

INICIO/Noticias Farmacéuticas | Posted 14/10/2016 0 Post your comment

Generics manufacturer Dr Reddy’s Laboratories (Dr Reddy’s) is expanding its collaboration with US-based biologicals specialist Amgen with an agreement to market and distribute three of Amgen’s biological medicines in India in the therapy areas of oncology and osteoporosis.

The announcement, which came on 16 September 2016, covers the commercialization of Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India. Xgeva is used to prevent fractures in patients with bone metastases from solid tumours. While Vectibix is a treatment for colon cancer and Prolia is an osteoporosis treatment for postmenopausal women at high risk for fracture.

Dr Reddy’s first announced its strategic collaboration with Amgen in 2015. This initial collaboration involved Dr Reddy’s executing a full range of regulatory and commercial services to seek approval of and launch Amgen’s multiple myeloma treatment Kyprolis (carfilzomib), leukaemia treatment Blincyto (blinatumomab) and high cholesterol treatment Repatha (evolocumab) in India.

The collaboration, according to Dr Reddy’s, ‘combines Amgen’s innovative therapies with Dr Reddy’s deep understanding of patient and physician needs in India’. It also strengthens the company’s ‘constant endeavour to enhance patient’s access to novel treatment options across therapy areas’, according to MV Ramana, Executive Vice President and Head of Emerging Markets and India Business, Dr Reddy’s. While Amgen’s Vice President and General Manager, Japan Asia-Pacific Region, Penny Wan, said ‘we are pleased with the commitment Dr Reddy’s has demonstrated toward making our medicines available in India as quickly as possible’.

Both Amgen and Dr Reddy’s are also making deals in the biosimilars field. In July 2016, Amgen made a deal with Japan-based Daiichi Sankyo for the commercialization of nine biosimilars in Japan [1]. While, in March 2016, Dr Reddy’s made a deal with Turkish pharma start-up firm TRPharm for a portfolio of biosimilars in Turkey [2].

Related articles
Dr Reddy’s to buy US generics from Teva

Dr Reddy’s buys six OTC brands from Ducere Pharma

References
1. GaBI Online - Generics and Biosimilars Initiative. Amgen and Daiichi Sankyo make deal for biosimilars in Japan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Oct 14]. Available from: www.gabionline.net/Pharma-News/Amgen-and-Daiichi-Sankyo-make-deal-for-biosimilars-in-Japan
2. GaBI Online - Generics and Biosimilars Initiative. Dr Reddy’s and TRPharm collaborate on biosimilars in Turkey [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Oct 14]. Available from: www.gabionline.net/Pharma-News/Dr-Reddy-s-and-TRPharm-collaborate-on-biosimilars-in-Turkey

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Dr Reddy’s, EMA